Decheng Capital

  • About Us
  • Team
  • Portfolio
  • News
  • Contact

A Global Life Sciences Investment Firm

Established in 2012

$2 Billion of Capital

Building Legendary Companies

In The News

December 8, 2017 EpiMab Biotherapeutics Wins Fortune China Innovation of the Year
November 13, 2017 Arcus Biosciences Announces $107 Million Series C Financing Led by GV and Initiation of Two Clinical Trials
August 29, 2017 ARMO BioSciences Raises $67 Million in a Series C-1 Financing
May 31, 2017 GRAIL and Cirina Combine to Create Global Company Focused on Early Detection of Cancer
May 8, 2017 Aadi Bioscience Closes $23 Million in Series A Funding
May 3, 2017 Hummingbird Bioscience, a rapidly growing therapeutic antibody discovery company today announced it has closed a venture funding round of an undisclosed amount from Decheng Capital
April 25, 2017 EpimAb Biotherapeutics Raises $25M in Series A Financing From International Consortium to Advance Pipeline of Novel Bispecific Antibodies
April 12, 2017 Nature Biotechnology Features ReadCoor As A 2016 Leading Spinout
April 11, 2017 Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors
March 19, 2017 Professor Dennis Lo, Decheng’s Advisor, Received the 2016 Future Science Prize Award

Archive

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012

    • Silicon Valley
    • Shanghai
    • New York